In vitro activity of dalbavancin against staphylococci isolated in Istanbul, Turkey.
Staphylococci are a major cause of both community- and hospital-acquired infections. Dalbavancin is a new bactericidal second-generation lipoglycopeptide antibiotic to use in the treatment of multidrug-resistant staphylococcal infections. It is important to determine its activity against staphylococci isolated in Turkey. Dalbavancin has not yet been used in antimicrobial therapy in our country. Dalbavancin was tested against a total of 453 staphylococcal strains by using the reference broth microdilution method. Organisms tested included: methicillin-resistant Staphylococcus aureus (MRSA; 237 strains), methicillin-susceptible S. aureus (MSSA; 144 strains) and methicillin- resistant coagulase-negative staphylococci (MR-CoNS; 72 strains). MIC(50) and MIC(90) values of dalbavancin against MRSA, MSSA and MR-CoNS were found as ≤0.008 and 0.25 mg/l; 0.016 and 0.125 mg/l; and 0.016 and 0.5 mg/l, respectively. The overall distribution of dalbavancin MIC values ranged from ≤0.008 to 2 mg/l. If the interpretive breakpoint MIC value is ≤1 mg/l, the susceptibility rates of MRSA, MSSA and MR-CoNS strains were determined as 99.6, 100 and 98.6%, respectively. The MIC results for dalbavancin have demonstrated a good activity against both methicillin-sensitive and -resistant staphylococci isolated from hospitalized patients.